The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma

Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1

(2010) Chie Nishioka et al.   APOPTOSIS

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

(2010) Jieru Meng et al.   CANCER BIOLOGY & THERAPY

Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim

(2010) W. Zhang et al.   CANCER RESEARCH

Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells

(2010) Y. N. V. Gopal et al.   CANCER RESEARCH

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

(2010) E. B. Haura et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

(2010) U. Banerji et al.   CLINICAL CANCER RESEARCH

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

(2010) John D. Hainsworth et al.   Journal of Thoracic Oncology

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis

(2010) Tri K. Nguyen et al.   LEUKEMIA RESEARCH

Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer

(2010) J. J. Tentler et al.   MOLECULAR CANCER THERAPEUTICS

KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

(2010) Young-Kwang Yoon et al.   MOLECULAR CARCINOGENESIS

Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim

(2010) Jieru Meng et al.   PLoS One

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

(2009) R E Board et al.   BRITISH JOURNAL OF CANCER

Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma

(2009) B. Dai et al.   CANCER RESEARCH

Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95

(2008) M. A. Park et al.   MOLECULAR CANCER THERAPEUTICS

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

(2008) Jer-Yen Yang et al.   NATURE CELL BIOLOGY